<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Patient-derived organoids model treatment response of metastatic gastrointestinal cancers</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2018-08-28">2018 August 28.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Georgios</forename><surname>Vlachogiannis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Somaieh</forename><surname>Hedayat</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexandra</forename><surname>Vatsiou</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yann</forename><surname>Jamin</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Javier</forename><surname>Fernández-Mateos</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Khurum</forename><surname>Khan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Lampis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katherine</forename><surname>Eason</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ian</forename><surname>Huntingford</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosemary</forename><surname>Burke</surname></persName>
							<affiliation key="aff4">
								<orgName type="laboratory">Cancer Research UK Cancer Therapeutics Unit</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mihaela</forename><surname>Rata</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dow-Mu</forename><surname>Koh</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nina</forename><surname>Tunariu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Collins</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sanna</forename><surname>Hulkki-Wilson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chanthirika</forename><surname>Ragulan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inmaculada</forename><surname>Spiteri</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sing</forename><forename type="middle">Yu</forename><surname>Moorcraft</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ian</forename><surname>Chau</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sheela</forename><surname>Rao</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Watkins</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicos</forename><surname>Fotiadis</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Bali</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mahnaz</forename><surname>Darvish-Damavandi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hazel</forename><surname>Lote</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zakaria</forename><surname>Eltahir</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elizabeth</forename><forename type="middle">C</forename><surname>Smyth</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruwaida</forename><surname>Begum</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
							<affiliation key="aff4">
								<orgName type="laboratory">Cancer Research UK Cancer Therapeutics Unit</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><forename type="middle">C</forename><surname>Hahne</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mitchell</forename><surname>Dowsett</surname></persName>
							<affiliation key="aff6">
								<orgName type="laboratory">Ralph Lauren Centre for Breast Cancer Research</orgName>
								<orgName type="institution">Royal Marsden Hospital NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johann</forename><surname>De Bono</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Division of Clinical Studies</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Workman</surname></persName>
							<affiliation key="aff4">
								<orgName type="laboratory">Cancer Research UK Cancer Therapeutics Unit</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anguraj</forename><surname>Sadanandam</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matteo</forename><surname>Fassan</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Surgical Pathology and Cytopathology Unit</orgName>
								<orgName type="institution">University of Padua</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Owen</forename><forename type="middle">J</forename><surname>Sansom</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Beatson Institute for Cancer Research</orgName>
								<address>
									<settlement>Glasgow</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Suzanne</forename><surname>Eccles</surname></persName>
							<affiliation key="aff4">
								<orgName type="laboratory">Cancer Research UK Cancer Therapeutics Unit</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Naureen</forename><surname>Starling</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Braconi</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="laboratory">Cancer Research UK Cancer Therapeutics Unit</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Sottoriva</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><forename type="middle">P</forename><surname>Robinson</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Research UK Cancer Imaging Centre</orgName>
								<orgName type="department" key="dep2">Division of Radiotherapy and Imaging</orgName>
								<orgName type="institution">The Institute of Cancer Research and Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Cunningham</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Nicola</forename><surname>Valeri</surname></persName>
							<email>nicola.valeri@icr.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Division of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The Royal Marsden NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Centre of Molecular Pathology</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<addrLine>15 Cotswold Road</addrLine>
									<postCode>SM2 5NG</postCode>
									<settlement>Belmont, Sutton Surrey</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Patient-derived organoids model treatment response of metastatic gastrointestinal cancers</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2018-08-28">2018 August 28.</date>
						</imprint>
					</monogr>
					<idno type="MD5">FE276F368A865F5A878948057D2D23B2</idno>
					<idno type="DOI">10.1126/science.aao2774</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Patient-derived organoids (PDOs) have recently emerged as robust pre-clinical models, however, their potential to predict patient clinical outcomes remain unclear.</s><s>We report a living biobank of PDOs from metastatic, heavily-pretreated colorectal and gastroesophageal cancer patients recruited in phase I/II clinical trials.</s><s>Phenotypic and genotypic profiling of PDOs showed a high-*</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>degree of similarity to the original patient tumor.</s><s>Molecular profiling of tumor organoids was matched to drug screening results, suggesting PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses.</s><s>We compared ex vivo organoid responses to anticancer agents, and PDO-based orthotopic mouse tumor xenograft models to the response of the patient in clinical trials.</s><s>Our data suggest that PDOs can recapitulate patient responses in the clinic, and have the potential to be implemented in personalized medicine programs.</s></p><p><s>High-throughput sequencing has been extensively used in precision medicine to identify somatic mutations that can be exploited for cancer treatment and drug development <ref type="bibr" target="#b0">(1)</ref>.</s><s>However, the limited role of genomic profiling in predicting response to targeted therapies, and limitations of pre-clinical models currently used for drug validation, represent important obstacles hampering the success of personalized medicine <ref type="bibr" target="#b1">(2)</ref>.</s><s>Co-clinical trials are defined as parallel studies where drug response in patients are matched to laboratory pre-clinical models, in order to personalize treatment and understand mechanisms of chemo-sensitivity through functional genomics and reverse translation <ref type="bibr" target="#b2">(3)</ref>.</s><s>Most co-clinical trials rely on the use of genetically engineered mouse models or patient-derived xenografts, posing logistic, ethical, and economic issues (4).</s></p><p><s>LGR5 + stem cells can be isolated from a number of organs and propagated as epithelial organoids in vitro to study physiology and neoplastic transformation <ref type="bibr" target="#b4">(5)</ref>.</s><s>Most studies on human colorectal cancer (CRC) organoids have been conducted on cultures derived from primary tumors <ref type="bibr" target="#b5">(6)</ref>.</s><s>In contrast, examples of PDOs from metastatic cancer sites remain sparse <ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref>.</s><s>Furthermore, very limited evidence is available on the ability of PDOs to predict response to treatment in the clinic <ref type="bibr" target="#b9">(10)</ref>.</s><s>Here we present a living biobank of PDOs from heavily-pretreated metastatic gastrointestinal cancer patients, and show examples of how these cancer organoids can be used to compare drug responses to those of the actual patient.</s></p><p><s>A total of 110 fresh biopsies from 71 patients enrolled in four prospective phase I/II clinical trials were processed between October 2014 and February 2017.</s><s>In line with previous data <ref type="bibr" target="#b6">(7)</ref>, PDOs were grown from 70% of biopsies with a cellularity of 2+ and above, and their establishment rate strongly correlated with tumor cellularity in the parental biopsy (χ 2 p&lt;0.0001).</s><s>No inverse correlation was observed between PDO establishment rate and presence of necrosis (cut-off ≥20%).</s><s>Tumor percentage is a key limiting factor for genomic and transcriptomic analyses.</s><s>When the 60% threshold used in large sequencing studies of primary CRC <ref type="bibr" target="#b10">(11)</ref> or gastroesophageal cancers (GOC) <ref type="bibr" target="#b11">(12)</ref> was applied in our cohort, we found no correlation between PDO take-up rate and tumor percentage, suggesting that PDOs can also be established in cases of a low tumor/stroma ratio thus allowing the ex vivo expansion of the cancer population in samples that would have otherwise failed quality control for next generation sequencing (NGS).</s></p><p><s>PDOs presented in this study were derived from ultrasound (n=20), computer-tomography (CT)-guided (n=7) or endoscopic (n=2) biopsies of metastatic CRC [mCRC; (n=16)], metastatic GOC [mGOC; (n=4)], and metastatic cholangiocarcinoma (n=1) patients (fig.</s><s><ref type="figure" target="#fig_1">S1</ref>).</s><s>Liver, pelvic, peritoneal, and nodal metastases of chemo-refractory patients were used to establish PDOs.</s><s>In several cases PDOs were established from sequential biopsies at baseline (BL), at the time of best response [partial response (PR) or stable disease (SD)], and at the time of disease progression (PD), as well as from multi-region biopsies (table <ref type="table">S1</ref>).</s></p><p><s>Histological evaluation revealed significant morphological similarities between PDOs and the patient biopsies from which they were originally-derived (Fig. <ref type="figure" target="#fig_1">1A</ref>, Fig. <ref type="figure" target="#fig_1">1B</ref>, fig.</s><s><ref type="figure" target="#fig_3">S2A</ref> and fig.</s><s><ref type="figure" target="#fig_3">S2B</ref>).</s><s>Immunohistochemistry markers routinely used in the diagnosis of CRC (CDX-2, CK7) showed that the parental tumor's expression pattern was maintained in PDOs, even when derived from sequential biopsies during treatment (fig.</s><s><ref type="figure" target="#fig_3">S2C</ref>, fig.</s><s><ref type="figure" target="#fig_3">S2D</ref> and fig.</s><s><ref type="figure" target="#fig_3">S2E</ref>).</s><s>Similarly, amplification of oncogenic drivers such as ERBB2 (Fig. <ref type="figure" target="#fig_1">1C</ref> and fig.</s><s><ref type="figure" target="#fig_3">S2F</ref>) or rearrangements in FGFR2 (fig.</s><s><ref type="figure" target="#fig_3">S2G</ref>) were retained in PDOs from mGOC and metastatic cholangiocarcinoma respectively.</s></p><p><s>NGS was used to profile 151 cancer-related genes in both PDOs (n=23) and their parental biopsies; archival material from primary cancer or pre-treatment diagnostic biopsy was also sequenced for 8 patients, and whole-genome sequencing (WGS) was performed for one PDO (table <ref type="table">S2</ref> and table <ref type="table">S3</ref>).</s><s>The molecular landscape of our PDOs (Fig. <ref type="figure" target="#fig_1">1D</ref>) largely overlapped that reported for mCRC and mGOC in the MSK-IMPACT study <ref type="bibr" target="#b0">(1)</ref>, with the exception of SRC and EGFR amplifications and ATM and BRCA2 mutations that were more frequent in our mCRC PDO cohort (table <ref type="table">S4</ref>).</s><s>Overall, 96% overlap in mutational spectrum was observed between PDOs and their parental biopsies (Fig. <ref type="figure" target="#fig_1">1D</ref>), while intratumor heterogeneity was observed between archival material (primary cancer) and metastatic deposits (biopsy or PDOs) (fig.</s><s><ref type="figure" target="#fig_4">S3A</ref> and table <ref type="table">S2</ref>).</s><s>Interestingly PDOs were able to capture spatio-temporal intra-tumor heterogeneity when established from multiple biopsies at time of disease progression compared to PDOs at the beginning of treatment (Fig. <ref type="figure" target="#fig_1">1D</ref>, fig.</s><s><ref type="figure" target="#fig_4">S3A</ref> and table <ref type="table">S2</ref>).</s><s>Similar findings were observed for copy number alterations (CNAs) in PDOs and biopsies collected at different time-points during treatment (fig.</s><s><ref type="figure" target="#fig_4">S3B</ref> and fig.</s><s><ref type="figure" target="#fig_5">S4</ref>).</s><s>WGS confirmed CNAs extrapolated from targeted NGS of PDOs or PDO-derived orthotopic tumors (PDO-xenografts) (fig.</s><s><ref type="figure" target="#fig_4">S3B</ref> and fig.</s><s><ref type="figure" target="#fig_5">S4</ref>); CNAs detected in key oncogenic drivers were further validated by digital-droplet PCR (fig.</s><s><ref type="figure">S5</ref>).</s><s>High concordance was observed in mutational, CNA, and transcriptomic profiling over successive passages when PDOs were tested before and after several months of continuous culture (passage range: 5-13); mutations: R 2 =0.96 p&lt;0.0001;</s><s>CNA: R 2 =0.97 p&lt;0.0001; gene expression (RNA-Seq): R 2 =0.7 p&lt;0.001 (fig.</s><s><ref type="figure">S6</ref>).</s></p><p><s>Next we tested the feasibility of using PDOs derived from metastatic cancers as drug screening tools, and validated the robustness of our approach by identifying several genotype-drug phenotype correlations across the PDO panel.</s><s>We ran 3D screening assays over a period of two weeks, (fig.</s><s><ref type="figure">S7</ref> and fig.</s><s><ref type="figure">S8</ref>) using a library of 55 drugs currently in phase I-III clinical trials or in clinical practice (table <ref type="table">S5</ref>).</s><s>The heatmap shown in fig.</s><s><ref type="figure">S9A</ref> summarizes screening data; hit validation at lower drug concentrations is reported in fig.</s><s><ref type="figure">S9B</ref>.</s><s>For all 19 screens a very high correlation was observed among each screen's three replicate assays and controls (fig.</s><s><ref type="figure" target="#fig_1">S10</ref>).</s></p><p><s>F-013 was the only ERBB2-amplified PDO in our cohort (Fig. <ref type="figure" target="#fig_1">1C</ref>), and it exhibited the strongest response to lapatinib (dual ERBB2/EGFR inhibitor); indeed, lapatinib potently inhibited the MAPK and PI3K/AKT signaling downstream of EGFR/ERBB2, inducing apoptosis in the F-013 PDO (Fig. <ref type="figure" target="#fig_1">1E</ref> and fig.</s><s><ref type="figure">S9A</ref>).</s><s>Interestingly, in a PDO (F-014) that harbors amplified EGFR but no ERBB2 amplification, lapatinib had no effect on viability and only modestly reduced MAPK and PI3K/AKT signaling (Fig. <ref type="figure" target="#fig_1">1E</ref> and fig.</s><s><ref type="figure">S9A</ref>).</s></p><p><s>Similarly, across all PDOs, F-016 was the only tumor carrying an AKT1-amplification and E17K mutation (Fig. <ref type="figure" target="#fig_1">1D</ref>), and is the only one strongly responding to both AKT inhibitors present in the drug library (MK-2206, GSK690693) (Fig. <ref type="figure" target="#fig_1">1E</ref> and fig.</s><s><ref type="figure">S9A</ref>).</s><s>One mCRC PDO (C-004) harbored a BRAF V600E mutation (Fig. <ref type="figure" target="#fig_1">1D</ref>) and is the only PDO that showed significantly decreased viability following treatment with the BRAF inhibitor vemurafenib (fig.</s><s><ref type="figure">S9A</ref>).</s><s>Consistent with this, vemurafenib selectively inhibited MEK/ERK signaling in the C-004 PDO (Fig. <ref type="figure" target="#fig_1">1E</ref>), but failed to induce apoptosis in keeping with the lack of efficacy of single agent BRAF inhibitors in mCRC <ref type="bibr" target="#b12">(13)</ref>.</s></p><p><s>Overall, PIK3CA mutations were not predictive of response to GDC-0980 (a dual PI3K/ mTOR inhibitor) in the PDOs panel (Fig. <ref type="figure" target="#fig_1">1D</ref> and fig.</s><s><ref type="figure">S9A</ref>).</s><s>In line with this observation, in a patient where pre-and post-treatment PDOs were established from multiple metastases (R-009 BL, PD-A and PD-B), a PIK3CA H1047R mutation common to all the PDOs was not associated with any response to GDC-0980.</s><s>However, PDOs carrying a synchronous PIK3CA amplification (R-009 PD-A) showed a dose-dependent reduction in cell viability in response to GDC-0980 (Fig. <ref type="figure" target="#fig_1">1F</ref> and fig.</s><s><ref type="figure" target="#fig_4">S3A</ref>).</s><s>Finally, in keeping with published data ( <ref type="formula">14</ref>), a significant correlation was observed between RB1 amplification and sensitivity of PDOs to palbociclib [CDK4/CDK6 inhibitor; (Fig. <ref type="figure" target="#fig_1">1G</ref>)].</s></p><p><s>Following extensive molecular and functional characterization of our PDOs, we examined their clinical predictive value by comparing clinical responses observed in patients with ex vivo-response data gathered in organoids in 21 comparisons (table <ref type="table">S6</ref>).</s><s>Taxanes are a standard second line treatment option for metastatic gastric cancer, however, efficacy is modest and no predictive biomarkers are available to inform clinical decisions <ref type="bibr" target="#b14">(15)</ref>.</s><s>We compared response to paclitaxel in sequential PDOs established before and after treatment in a paclitaxel-sensitive patient (F-014) with PDOs established from liver metastases of two paclitaxel-resistant patients (Fig. <ref type="figure" target="#fig_3">2A</ref> and Fig. <ref type="figure" target="#fig_3">2B</ref>).</s><s>PDOs derived from the responsive metastasis showed a ~4-fold lower GI 50 for clinically relevant paclitaxel concentrations ( <ref type="formula">16</ref>) compared with PDOs from the same patient derived at progression; interestingly, these resistant PDOs demonstrated an identical paclitaxel dose-response profile to the two PDOs established from paclitaxel-refractory patients (Fig. <ref type="figure" target="#fig_3">2B</ref>).</s><s>Cell cycle analysis showed marked apoptosis and G2 arrest upon taxane treatment in the pre-treatment F-014 PDOs, while no significant difference was observed in PDOs established at progression (Fig. <ref type="figure" target="#fig_3">2C</ref> and fig.</s><s><ref type="figure" target="#fig_1">S11A</ref>).</s><s>Similarly, paclitaxel induced dose-dependent DNA damage, mitotic arrest and apoptosis in the pre-treatment F-014 PDOs, but had a much weaker impact on the progression (thus resistant) PDOs (Fig. <ref type="figure" target="#fig_3">2D</ref>).</s><s>Consistent with data observed for second line treatment, a ~10-fold difference in GI 50 was observed in response to the combination of 5fluorouracil and cisplatin in PDOs collected from chemo-sensitive and chemo-refractory mGOC patients receiving first-line treatment (fig.</s><s><ref type="figure" target="#fig_1">S11B</ref>), highlighting the clinical potential of PDOs for treatment selection in cancers of unmet need.</s></p><p><s>Anti-EGFR monoclonal antibodies, regorafenib, and TAS-102 represent FDA approved options for treatment of chemo-refractory mCRC, however, with the exception of RAS pathway mutations for anti-EGFR therapy, there are no validated clinical biomarkers for patient selection in this setting.</s><s>We initially tested the predictive value of PDOs in mCRC by comparing response to anti-EGFR treatment with cetuximab in five PDOs and their respective patients (Fig. <ref type="figure" target="#fig_3">2E</ref>).</s><s>Two PDOs established from baseline biopsies prior to anti-EGFR treatment in the PROSPECT-C trial showed no response to cetuximab, in keeping with the primary resistance observed in these two patients in the clinic.</s><s>Unsurprisingly <ref type="bibr" target="#b16">(17)</ref>, both PDOs and their respective patient biopsies harbored either KRAS G12D (sub-clonal) or BRAF V600E (clonal) mutations (Fig. <ref type="figure" target="#fig_3">2F</ref>).</s><s>The third cetuximab-resistant PDO (C-002) was established from the progression biopsy of a patient who initially responded to cetuximab, and, interestingly, it harbored an EGFR amplification (Fig. <ref type="figure" target="#fig_1">1D</ref> and fig.</s><s><ref type="figure">S5</ref>), no RAS pathway mutational aberrations (Fig. <ref type="figure" target="#fig_3">2F</ref>), and high amphiregulin mRNA levels.</s><s>Despite these molecular markers being suggestive of responsiveness to cetuximab, the C-002 PDO showed no response (and in fact paradoxical enhanced proliferation) upon cetuximab treatment in line with the respective patient's clinical outcome, thus highlighting the potential of PDOs to better predict clinical outcomes compared to molecular pathology alone.</s><s>Another KRASwild type PDO derived from a slow growing progressing metastasis in a patient with otherwise stable disease [C-001; (fig.</s><s><ref type="figure" target="#fig_1">S11C</ref>)] showed a marginal response to cetuximab.</s><s>Finally, the KRAS-wild type PDO established from a BL biopsy of a patient enrolled in the PROSPECT-R trial [R-007; (fig.</s><s><ref type="figure" target="#fig_1">S11C</ref>)] showed response to cetuximab at doses higher than 5 µg/ml; this, however, could not be compared with clinical response as the patient did not receive anti-EGFR mAbs.</s></p><p><s>Next we tested the ability of PDOs to recapitulate response to regorafenib, a multiple tyrosine kinase inhibitor blocking oncogenic and angiogenic signaling pathways.</s><s>No response to regorafenib was observed in our 3D ex vivo screening assays (fig.</s><s><ref type="figure">S9A</ref>), an observation in keeping with our recently reported clinical results from the PROSPECT-R trial <ref type="bibr" target="#b17">(18)</ref> suggesting that response to regorafenib is mainly driven by its anti-angiogenic effect (Fig. <ref type="figure" target="#fig_4">3A</ref>).</s></p><p><s>In order to match response to regorafenib in the clinic and in aligned PDOs we established an orthotopic human tumor xenograft model by implanting luciferase-expressing (Luc+) PDOs in the liver of NSG mice [PDO-xenografts; (fig.</s><s><ref type="figure" target="#fig_3">S12A</ref>)].</s><s>We initially compared response to regorafenib in PDO-xenografts from a patient with primary resistance [R-009 (n=11)] and from a patient who achieved a durable (10 months) response [R-005 (n=6)] to regorafenib (fig.</s><s><ref type="figure" target="#fig_3">S12B</ref> and fig.</s><s><ref type="figure" target="#fig_3">S12C</ref>).</s><s>In keeping with clinical response (Fig. <ref type="figure" target="#fig_4">3A</ref>), PDOxenografts from the regorafenib-sensitive patient displayed a significant (p=0.03)</s><s>reduction in their micro-vasculature in response to regorafenib as revealed by CD31 immunostaining; in contrast, no significant changes were observed in PDO-xenografts from the regorafenibresistant patient (Fig. <ref type="figure" target="#fig_4">3B</ref>).</s><s>In order to mimic our clinical observations, we performed functional susceptibility-contrast magnetic resonance imaging (MRI) in PDO-xenografts of the responder patient [R-005 (n=10)] before and after treatment (fig.</s><s><ref type="figure" target="#fig_3">S12D</ref>).</s><s>In line with dynamic contrast-enhanced MRI (DCE-MRI) results in patients (Fig. <ref type="figure" target="#fig_4">3A</ref>), susceptibilitycontrast MRI revealed a significant reduction in tumor fractional blood volume (fBV) in regorafenib-treated mice (Fig. <ref type="figure" target="#fig_4">3C</ref>).</s><s>These changes were associated with a reduction in CD31 staining and increased necrosis (Fig. <ref type="figure" target="#fig_4">3C</ref>).</s><s>Remarkably, across all animals, a robust correlation was observed between the fBV values obtained from susceptibility contrast MRI and the micro-vasculature assessment [CD31 (R 2 =0.64 p=0.006)] of the same samples (Fig. <ref type="figure" target="#fig_4">3C</ref>).</s><s>Interestingly, in line with our clinical data, changes in micro-vasculature indicative of response appeared to be independent of changes in tumor volume (fig.</s><s><ref type="figure" target="#fig_3">S12E</ref>) <ref type="bibr" target="#b17">(18)</ref>.</s><s>Three different histopathological growth patterns [(HGPs); desmoplastic HGP; pushing HGP; replacement HGP] have been associated with different degrees of response to antiangiogenic drugs, with the replacement HGP being frequently associated with vessel cooption and primary resistance <ref type="bibr" target="#b18">(19)</ref>.</s><s>In our experiments a predominance of replacement HGP, and thus vessel co-option, was observed in PDO-xenografts from the resistant patient, whilst tumors established from the PDOs of the sensitive patient showed prevalence of desmoplastic and pushing HGPs (fig.</s><s><ref type="figure" target="#fig_3">S12F</ref>), suggesting that vessel co-option might be the mechanism underpinning primary resistance to regorafenib.</s><s>When the responder to regorafenib (R-005) progressed and received subsequent treatment, he was enrolled in a phase I trial of the ATR inhibitor VX-970.</s><s>No response was observed in this patient with VX-970 monotherapy, and this was in keeping with lack of response to ATM/ATR inhibitors observed in his PDOs in the drug screening reported in fig.</s><s><ref type="figure">S9A</ref>.</s></p><p><s>In order to test the PDOs' ability to capture tumor evolution and acquired resistance to treatment, we generated xenografts using PDOs from the same liver metastasis before (BL) and after treatment (PD) in mCRC patient R-011 that exhibited initial response and subsequent progression to regorafenib (fig.</s><s><ref type="figure" target="#fig_4">S13A</ref>).</s><s>Mice were randomized to treatment and control arms, and, following treatment, each arm was further randomized for survival or functional analysis (Fig. <ref type="figure" target="#fig_4">3D</ref>).</s><s>In line with clinical findings (Fig. <ref type="figure" target="#fig_4">3E</ref>) <ref type="bibr" target="#b17">(18)</ref>, CD31 immunostaining revealed a ~60% reduction in micro-vasculature in response to regorafenib in BL PDO-xenografts, while no significant change was observed in PD PDO-xenografts [p: 0.001; (Fig. <ref type="figure" target="#fig_4">3F</ref>)].</s><s>More importantly, regorafenib treatment offered a selective survival benefit in mice carrying BL PDO-xenografts (Fig. <ref type="figure" target="#fig_4">3G</ref> and fig.</s><s><ref type="figure" target="#fig_4">S13B</ref>), confirming the predictive value of PDOs and their ability to reflect cancer evolution upon treatment.</s></p><p><s>TAS-102, a combination of the nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil, is approved for the treatment of chemo-refractory mCRC but no validated bio-markers are currently available <ref type="bibr" target="#b19">(20)</ref>.</s><s>We compared clinical and preclinical response to TAS-102 in 6 organoids from 4 different patients treated with TAS-102.</s><s>Initially we tested response to TAS-102 in PDOs from a patient (R-019) who had a mixed response, with stability of disease in one of the liver metastases (segment 5) and rapid progression in another one (segment 2) (Fig. <ref type="figure" target="#fig_5">4A</ref>).</s><s>Ex vivo dose-response data showed a ~8fold difference in GI50 between PDOs derived from the TAS-102 sensitive metastasis and those derived from pre-and post-treatment biopsy of the rapidly progressing metastasis (Fig. <ref type="figure" target="#fig_5">4B</ref>), highlighting the ability of PDOs to recapitulate intra-patient heterogeneity.</s><s>TK1 has been proposed as a potential biomarker of response to TAS-102 <ref type="bibr" target="#b20">(21)</ref>; interestingly, TK1 protein expression was indeed higher in PDOs from the responding metastasis compared with those from the non-responding site (Fig. <ref type="figure" target="#fig_5">4C</ref>).</s><s>When we extended the TAS-102 sensitivity analysis to 3 other PDOs/patients we confirmed that PDOs from patients who achieved disease control were sensitive to low uM concentrations of TAS-102, while no significant effect on cell viability was observed in PDOs from resistant (primary or acquired) patients (Fig. <ref type="figure" target="#fig_5">4D</ref>, left); in line with previous data, TK1 mRNA expression was higher in PDOs from patients that achieved stable disease in response to TAS-102 (Fig. <ref type="figure" target="#fig_5">4D</ref>, right).</s></p><p><s>Overall, for the PDOs we analyzed, we found 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value in forecasting response to targeted agents or chemotherapy in patients [Fisher's exact test p&lt;0.0001;</s><s>(table <ref type="table">S7</ref>)].</s><s>Our data suggest that PDOs can be exploited for functional genomics to simulate cancer behavior ex vivo and integrate molecular pathology in the decision-making process of early phase clinical trials.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Refer to Web version on PubMed Central for supplementary material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Europe PMC Funders Author Manuscripts</head><p><s>Europe PMC Funders Author Manuscripts</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>One Sentence Summary</head><p><s>Patient-derived organoids predict response of metastatic gastrointestinal cancers to therapy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>34. Troprès I, et al.</s><s>In vivo assessment of tumoral angiogenesis.</s><s>Magnetic Resonance in Medicine.</s><s>2004; 51(3):533-541.</s><s>[PubMed: 15004795] Vlachogiannis et al.</s><s>Page 9 Science.</s><s>Author manuscript; available in PMC 2018 August 28.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Histopathological, molecular, and functional characterization of patient-derived organoids (PDOs).</s></p></div></figDesc><graphic coords="11,111.36,62.00,449.28,503.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>(</head><label></label><figDesc><div><p><s>A) Phase-contrast image of a mCRC PDO culture, and H&amp;E staining comparing organoids to their matching patient biopsy.</s><s>(B) Diffuse and intestinal growth patterns are retained in mGOC PDOs.</s><s>(C) ERBB2 amplification and over-expression in mGOC PDOs and parental tissue biopsy; CISH= chromogenic in situ hybridization.</s><s>(D) Heatmap displaying the most frequently mutated and/or copy number altered genes in PDOs (left).</s><s>Venn diagram demonstrating 96% mutational overlap between PDOs and parental tissue biopsies (right).(E)</s><s>Target engagement in genotype-drug phenotype combinations: pathway analysis downstream of ERBB2 in ERBB2-amplified and non-amplified PDOs treated with lapatinib (24h) (right panel); BRAF inhibition (24h) (central panel); AKT inhibition (4h) (left panel).</s><s>(F) Dose-dependent effect to the dual PI3K/mTOR inhibitor GDC-0980 in three PDOs from patient R-009, all carrying an acquired PIK3CA mutation (H1047R).</s><s>PDOs established from a liver metastasis biopsied at disease progression (R-009 PD A) that also harbored PIK3CA amplification showed dose-dependent response to GDC-0980.</s><s>PIK3CA-mutant but nonamplified PDOs established prior to regorafenib treatment (R-009 BL) or from a different liver metastasis biopsied at disease progression (R-009 PD B) did not respond to GDC-0980.</s><s>Viability data show mean ± SEM of indicated independent experiments.</s><s>(G) Correlation (Fisher's exact test) between presence of RB1 amplification in PDOs (panel 1D) and response to the CDK4/CDK6 inhibitor palbociclib in the reported drug screen (fig.</s><s>S9A).</s><s>Abbreviations: BL= baseline; SD= stable disease; PD= post-treatment/progressive disease.</s><s>Vlachogiannis et al.</s><s>Page 12 Science.</s><s>Author manuscript; available in PMC 2018 August 28.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Patient-derived organoid-based ex vivo co-clinical trials in mGOC and mCRC.</s><s>(A) PDOs were generated from sequential biopsies of a liver metastasis (red circle in the bottom panel) of mGOC patient F-014 that showed initial response to paclitaxel (F-014 BL) and subsequently progressed (F-014 PD).</s><s>Violet bars indicate overall tumor volume (according to RECIST 1.1.</s><s>criteria) while red bars indicate volume of the target metastasis used to generate PDOs.</s><s>(B) Cell viability upon paclitaxel treatment was compared in baseline (BL) and progressive disease (PD) PDOs from patient F-014 treated with paclitaxel, and those derived from patients that exhibited primary (F-015) or acquired (F-012) resistance to paclitaxel in the clinic.</s><s>Viability data show mean ± SEM of indicated independent experiments.</s><s>(C) Cell cycle analysis upon paclitaxel treatment in the F-014 baseline (BL) PDO compared with the F-014 progressive disease (PD) PDO.</s><s>(D) Dosedependent DNA damage was observed in the F-014 baseline (BL) PDO in response to paclitaxel, but not in PDOs from the same patient established at progressive disease (PD).</s><s>(E) PDOs were established from baseline (BL) (C-003, C-004) and progressive disease (PD) (C-001, C-002) biopsies from patients treated with the anti-EGFR monoclonal antibody</s></p></div></figDesc><graphic coords="13,84.00,62.00,504.00,403.92" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Patient-derived organoid-based co-clinical trials mimic primary and acquired resistance to regorafenib in mice.(A)</s><s>mCRC patients on regorafenib treatment underwent biopsies at baseline (BL), partial response/stable disease stage (PR/SD), or post-treatment (PD).</s><s>An early reduction (15 days) in functional imaging (DCE-MRI) parameters correlated with changes in micro-vasculature assessed by CD31 staining and clinical benefit from regorafenib (right panel).</s><s>(B) Changes in micro-vasculature in response to regorafenib were assessed in PDO mouse xenografts by quantification of tumor-associated CD31-positive vessels.</s><s>Data show PDO xenografts from a</s></p></div></figDesc><graphic coords="15,106.68,62.00,458.64,503.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. Patient-derived organoids recapitulate intra-and inter-patient heterogeneity in response to TAS-102.</s><s>(A) PDOs were established from a patient (R-019) with mixed response to TAS-102.</s><s>While the segment 2 metastasis rapidly progressed, the segment 5 one remained stable upon TAS-102 treatment (white arrows in the CT-scan indicate metastases; bars indicate pre-and post-treatment measurement of the indicated metastases).</s><s>(B) Ex vivo dose-response curves in baseline (BL) and post-treatment (PD) multi-region PDOs from patient R-019 (with mixed response to TAS-102).</s><s>N= independent experiments; viability values are expressed as mean ± SEM. (C) TK1 immunohistochemistry (IHC) expression in TAS-102 refractory (segment 2) and sensitive (segment 5) PDOs.</s><s>BL = baseline; PD = post-treatment/ progressive disease.</s><s>(D) Cell viability (left) and TK1 mRNA expression (right) in PDOs from TAS-102 responsive and refractory patients.</s><s>BL= baseline; PD= post-treatment/ progressive disease.</s><s>N indicates independent experiments; viability values are expressed as mean ± SEM.</s></p></div></figDesc><graphic coords="17,84.00,62.00,504.00,331.92" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Science. Author manuscript; available in PMC 2018 August 28.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The data presented in this paper are tabulated in the main text and supplemental materials.</s><s>Sharing of materials is subject to a material transfer agreement (MTA) with the The Institute of Cancer Research, London (please direct requests to N.V).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zehir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="703" to="713" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28481359</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">DNA-guided precision medicine for cancer: a case of irrational exuberance?</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Voest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bernards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="130" to="132" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26851184</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Interrogating open issues in cancer precision medicine with patient-derived xenografts</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Byrne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="254" to="268" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28104906</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mouse hospital and co-clinical trial project--from bench to bedside</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Clohessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Pandolfi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="491" to="498" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25895610</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Human tissues in a dish: The research and ethical implications of organoid technology</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Bredenoord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Clevers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Knoblich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="issue">6322</biblScope>
			<biblScope unit="page">9414</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28104841</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prospective derivation of a living organoid biobank of colorectal cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Van De Wetering</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="933" to="945" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25957691</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases</title>
		<author>
			<persName><forename type="first">F</forename><surname>Weeber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">43</biblScope>
			<biblScope unit="page" from="13308" to="13311" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fujii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Stem Cell</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="827" to="838" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27212702</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Personalized in vitro and in vivo cancer models to guide precision medicine</title>
		<author>
			<persName><forename type="first">C</forename><surname>Pauli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="462" to="477" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28331002</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dekkers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science Translational Medicine</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">344</biblScope>
			<biblScope unit="page" from="344" to="384" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Comprehensive molecular characterization of human colon and rectal cancer</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">487</biblScope>
			<biblScope unit="issue">7407</biblScope>
			<biblScope unit="page" from="330" to="337" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>The Cancer Genome Atlas Research Network. PubMed: 22810696</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Comprehensive molecular characterization of gastric adenocarcinoma</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">513</biblScope>
			<biblScope unit="issue">7517</biblScope>
			<biblScope unit="page" from="202" to="209" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>The Cancer Genome Atlas Research Network. PubMed: 25079317</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Hyman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="726" to="736" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26287849</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Targeting CDK4 and CDK6: from discovery to therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Sherr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Shapiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="353" to="367" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26658964</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Smyth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of Oncology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">suppl_5</biblScope>
			<biblScope unit="page" from="38" to="49" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Zasadil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science Translational Medicine</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="229" to="243" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. eLife</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Verissimo</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e18489</biblScope>
		</imprint>
	</monogr>
	<note>PubMed: 27845624</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Khan</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2017-314178</idno>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Published Online First</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Frentzas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1294" to="1302" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27748747</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Randomized trial of TAS-102 for refractory metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mayer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1909" to="1919" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25970050</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, singlearm, multicentre, phase 1/2 study. The Lancet Oncology</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kuboki</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1172" to="1181" />
		</imprint>
	</monogr>
	<note>PubMed: 28760399</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads</title>
		<author>
			<persName><forename type="first">H</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="182" to="193" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24925680</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Fast and accurate short read alignment with Burrows-Wheeler transform</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Durbin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1754" to="1760" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19451168</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Integrating mapping-, assembly-and haplotype-based approaches for calling variants in clinical sequencing applications</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rimmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="912" to="918" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 25017105</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">CSN and CAVA: Variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting</title>
		<author>
			<persName><forename type="first">M</forename><surname>Münz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Medicine</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="76" to="83" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26315209</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing</title>
		<author>
			<persName><forename type="first">E</forename><surname>Talevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Shain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Botton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Bastian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Comput Biol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e1004873</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27100738</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">HISAT: a fast spliced aligner with low memory requirements</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Langmead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Salzberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Meth</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="357" to="360" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">StringTie enables improved reconstruction of a transcriptome from RNA-seq reads</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pertea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Pertea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Antonescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Salzberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotech</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="290" to="295" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Mapping and quantifying mammalian transcriptomes by RNA-Seq</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mortazavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mccue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Scaeffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Meth</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="621" to="628" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Ballgown bridges the gap between transcriptome assembly and expression analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Frazee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pertea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Langmead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Salzberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Leek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotech</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="243" to="246" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Guidelines for the welfare and use of animals in cancer research</title>
		<author>
			<persName><forename type="first">P</forename><surname>Workman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1555" to="1577" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20502460</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Improving bioscience research reporting: The ARRIVE guidlines for reporting animal research</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kilkenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Cuthill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Biol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e1000412</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20613859</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jkr</forename><surname>Boult</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Vasudev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Reynolds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="4127" to="4134" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28566330</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
